TrialClinical cancer research : an official journal of the American Association for Cancer Research2016

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.

Melinda L Telli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.